Kite Pharma

TECARTUS

Manufacturer:

Kite Pharma

Tecartus HCPCS:

Q2053

HCPCS Code Descriptor:

Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Category:

Q Code

Tecartus NDCs:

71287-0220-01, 71287-0219-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Tecartus:

TECARTUS is an Oncology drug manufactured by Kite Pharma and administered via the Intravenous route of administration. The Q Code: Q2053 is aligned to the drug TECARTUS.

ACCESS PRICING AND MORE BY REGISTERING

Q2053 Added Date:

April 1, 2021

Q2053 Effective Date:

April 1, 2021

Q2053 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Tecartus billing and coding information.
Tecartus patient assistance information can be found through Kite Konnect at the URL: https://www.kitekonnect.com/
TECARTUS prescribing information can be found at the link below:
Information regarding TECARTUS’s side effects can be found at MedlinePlus